The impact of PEAR 1 polymorphism on clinical outcomes in Chinese patients receiving dual antiplatelet therapy after percutaneous coronary intervention

被引：6
|
作者：
Hu, Xinyuan [1 ]
Liu, Chaoxi [2 ]
Zhang, Mingyou [2 ]
Zhang, Weihua [2 ]
机构：
[1] First Hosp Jilin Univ, Genet Diag Ctr, Changchun 130021, Peoples R China
[2] First Hosp Jilin Univ, Dept Cardiol, Changchun 130021, Peoples R China
来源：
PHARMACOGENOMICS | 2022年 / 23卷 / 11期
关键词：
aspirin; genetic polymorphisms; PCI; PEAR1; CLOPIDOGREL RESPONSIVENESS; PLATELET REACTIVITY; RECEPTOR;
D O I：
10.2217/pgs-2022-0033
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Background: Patients might still experience major adverse cardiovascular events even with dual antiplatelet therapy after percutaneous coronary intervention. Our study aimed to explore the impact of gene polymorphism on clinical outcomes in one-year follow-up. Methods: A total of 171 patients treated with dual antiplatelet therapy after percutaneous coronary intervention from April to December 2020 in the first hospital of Jilin University enrolled in this study. Results: PEAR1 genetic polymorphisms was associated with the arachidonic acid (AA) and adenosine diphosphate (ADP) platelet aggregation. Hyperglycemia was associated with the rate of major adverse cardiovascular events. PEAR1 GA+AA genetic genetic polymorphisms is associated with hyperglycemia. Conclusion: PEAR1 GG is a risk factor for AA and ADP platelet aggregation. Hyperglycemia can effect the one-year outcome. PEAR1 GA+AA genetic polymorphisms are associated with hyperglycemia.
引用
收藏
页码：639 / 648
页数：10
相关论文
共 50 条
  • [41] Dual Antiplatelet Therapy Benefited the Patients Received Percutaneous Coronary Intervention in Taiwan
    Chang, Chia-Hsien
    Yang, Yea-Huei Kao
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S264 - S264
  • [42] DURATION OF ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS ON ORAL ANTICOAGULANTS IN CLINICAL PRACTICE
    Tobolski, Jared
    Abbott, J.
    Kolte, Dhaval
    Curtis, Jeptha
    Hira, Ravi
    Wang, Yongfei
    Minges, Karl
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1081 - 1081
  • [43] Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention
    Yamamoto, Ko
    Watanabe, Hirotoshi
    Morimoto, Takeshi
    Obayashi, Yuki
    Natsuaki, Masahiro
    Yamaji, Kyohei
    Domei, Takenori
    Ogita, Manabu
    Ohya, Masanobu
    Tatsushima, Shojiro
    Suzuki, Hirohiko
    Tada, Tomohisa
    Ishii, Mitsuru
    Nikaido, Akira
    Watanabe, Naoki
    Fujii, Shinya
    Mori, Hiroyoshi
    Nishikura, Tenjin
    Suematsu, Nobuhiro
    Hayashi, Fujio
    Komiyama, Kota
    Shigematsu, Tatsuya
    Isawa, Tsuyoshi
    Suwa, Satoru
    Ando, Kenji
    Kimura, Takeshi
    JACC-CARDIOVASCULAR INTERVENTIONS, 2023, 16 (01) : 19 - 31
  • [44] Impact of CCBs on the Clinical Outcomes in Patients with Clopidogrel After Percutaneous Coronary Intervention
    Du, Meng-Yang
    Yuan, Jinqing
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (15) : S65 - S65
  • [45] Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention
    Bagai, Akshay
    Bhatt, Deepak L.
    Eikelboom, John W.
    Mancini, G. B. John
    Cohen, Eric A.
    Vijayaraghavan, Ram
    Cheema, Asim N.
    Udell, Jacob A.
    Niznick, Joel
    Tanguay, Jean-Francois
    Verma, Subodh
    Mehta, Shamir R.
    CIRCULATION, 2016, 133 (21) : 2094 - 2098
  • [46] Clinical outcomes of risk score-guided dual antiplatelet therapy in patients with acute coronary syndrome who underwent percutaneous coronary intervention
    Hyun, D.
    Lim, Y.
    Oh, S.
    Ahn, J. H.
    Lee, S. H.
    Cho, K. H.
    Kim, M. C.
    Hong, Y. J.
    Kim, J. H.
    Ahn, Y.
    Jeong, M. H.
    Sim, D. S.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [47] Dual antiplatelet therapy after percutaneous coronary intervention for left main coronary artery disease
    Cho, Sungsoo
    Kang, Do-Yoon
    Kim, Jung -Sun
    Park, Duk-Woo
    Kim, In-Soo
    Kang, Tae Soo
    Ahn, Jung -Min
    Lee, Pil Hyung
    Kang, Soo-Jin
    Lee, Seung-Whan
    Kim, Young-Hak
    Lee, Cheol Whan
    Park, Seong-Wook
    Lee, Seung-Jun
    Hong, Sung-Jin
    Ahn, Chul-Min
    Kim, Byeong-Keuk
    Ko, Young-Guk
    Choi, Donghoon
    Jang, Yangsoo
    Hong, Myeong-Ki
    Park, Seung-Jung
    REVISTA ESPANOLA DE CARDIOLOGIA, 2023, 76 (04): : 245 - 252
  • [48] Limitation of antiplatelet therapy after percutaneous coronary intervention
    Nomura, Shosaku
    Inami, Norihito
    Kimura, Yutaka
    Urase, Fumiaki
    Maeda, Yasuhiro
    Iwasaka, Toshiji
    PLATELETS, 2008, 19 (05) : 392 - 393
  • [49] Dual Antiplatelet Therapy After Percutaneous Coronary Intervention for Left Main Coronary Artery Disease
    Cho, Sungsoo
    Kang, Do-Yoon
    Kim, Jung-Sun
    Park, Duk-Woo
    Kim, In-Soo
    Kang, Tae Soo
    Ahn, Jung-Min
    Lee, Pil Hyung
    Kang, Soo-Jin
    Kim, Young-Hak
    Lee, Cheol Whan
    Park, Seong-Wook
    Lee, Yong-Joon
    Lee, Seung-Jun
    Hong, Sung-Jin
    Ahn, Chul-Min
    Kim, Byeong-Keuk
    Ko, Young-Guk
    Choi, Donghoon
    Jang, Yangsoo
    Hong, Myeong-Ki
    Park, Seung-Jung
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (12) : B61 - B62
  • [50] Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention
    Mizia-Stec, K.
    Haberka, M.
    Najda, J.
    Mizia, M.
    Gieszczyk, K.
    Lasota, B.
    Chmiel, A.
    Kyrcz-Krzemien, S.
    Gasior, Z.
    EUROPEAN HEART JOURNAL, 2010, 31 : 197 - 197
12345